Quinoline-derived amide modulators of vanilloid VR1 receptor

Abstract

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

1 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
       
       wherein: 
 R 1  is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
 m is 0, 1 or 2;  
 R 2  is hydrogen or C 1-8 alkanyl;  
 L is a direct bond or C 1-4 alkyldiyl optionally substituted with a substituent selected from the group consisting of C 1-8 alkanyl, C 3-8 cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, halogen, C 1-8 alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C 1-3 )alkanylamino, and C 1-3 alkanylamino;  
 R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl;  
 R 4  is independently selected from the group consisting of C 1-12 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 1-6 fluorinated alkanyl and —N(R 5 )(R 6 ); or when n is 2 or 3, optionally two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
 R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
 R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl;  
 wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
 n is 1, 2 or 3;  
 Z is O or S; and  
 enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
 
     
     
         2 . The compound according to  claim 1  wherein L is a direct bond.  
     
     
         3 . The compound according to  claim 1  wherein L is C 1-4 alkyldiyl.  
     
     
         4 . The compound according to  claim 1  wherein R 3  is phenyl.  
     
     
         5 . The compound according to  claim 1  wherein R 3  is pyridyl.  
     
     
         6 . The compound according to  claim 1  wherein R 3  is thienyl.  
     
     
         7 . The compound according to  claim 1  wherein n is 1.  
     
     
         8 . The compound according to  claim 1  wherein n is 2 or 3 and R 4  is C 1-12 alkanyl.  
     
     
         9 . The compound according to  claim 1  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         10 . The compound according to  claim 9  wherein R 5  and R 6  are different.  
     
     
         11 . The compound according to  claim 1  wherein L is Cl-4alkyldiyl, R 3  is phenyl, n is 1 and R 4  is C 1-12 alkanyl.  
     
     
         12 . The compound according to  claim 1  wherein R 3  is phenyl, n is 1 and R 4  is —N(R 5 )(R 6 ).  
     
     
         13 . The compound according to  claim 1  wherein R 3  is phenyl, n is 2 or 3, and two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkyl.  
     
     
         14 . The compound according to  claim 1  wherein Z is O.  
     
     
         15 . The compound according to  claim 1  wherein m is 0.  
     
     
         16 . The compound according to  claim 1  wherein R 2  is hydrogen.  
     
     
         17 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
         wherein:  
         R 1  is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
         m is 0, 1 or 2;  
         R 2  is hydrogen or C 1-8 alkanyl;  
         L is a C 1-4 alkyldiyl optionally substituted with a substituent selected from the group consisting of C 1-8 alkanyl, C 3-8 cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, halogen, C 1-8 alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C 1-3 )alkanylamino, and C 1-3 alkanylamino;  
         R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl;  
         R 4  is independently selected from the group consisting of C 1-12 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 1-6  fluorinated alkanyl, and —N(R 5 )(R 6 ); or when n is 2 or 3, optionally two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
         R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
         R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl;  
         wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
         n is 1, 2 or 3;  
         Z is O or S; and  
         enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
       
     
     
         18 . The compound according to  claim 17  wherein R 3  is phenyl.  
     
     
         19 . The compound according to  claim 17  wherein R 3  is pyridyl.  
     
     
         20 . The compound according to  claim 17  wherein R 3  is thienyl.  
     
     
         21 . The compound according to  claim 17  wherein n is 1.  
     
     
         22 . The compound according to  claim 17  wherein n is 2 or 3 and R 4  is C 1-12 alkanyl.  
     
     
         23 . The compound according to  claim 17  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         24 . The compound according to  claim 23  wherein R 5  and R 6  are different.  
     
     
         25 . The compound according to  claim 17  wherein L is C 1-4 alkyldiyl, R 3  is phenyl, n is 1 and R 4  is C- 1-12 alkanyl.  
     
     
         26 . The compound according to  claim 17  wherein R 3  is phenyl, n is 1 and R 4  is —N(R 5 )(R 6 ).  
     
     
         27 . The compound according to  claim 17  wherein R 3  is phenyl, n is 2 or 3, and two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkyl.  
     
     
         28 . The compound according to  claim 17  wherein Z is O.  
     
     
         29 . The compound according to  claim 17  wherein m is 0.  
     
     
         30 . The compound according to  claim 17  wherein R 2  is hydrogen.  
     
     
         31 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
         wherein:  
         R 1  is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
         m is 0, 1 or 2;  
         R 2  is hydrogen or C 1-8 alkanyl;  
         L is a direct bond or C 1-4 alkyldiyl optionally substituted with a substituent selected from the group consisting of C 1-8 alkanyl, C 3-8 cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, halogen, C 1-8 alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C 1-3 )alkanylamino, and C 1-3 alkanylamino;  
         R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl;  
         R 4  is independently selected from the group consisting of C 1-8 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 1-6  fluorinated alkanyl, and —N(R 5 )(R 6 ); or both R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
         R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
         R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl;  
         wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
         n is 2 or 3;  
         Z is O or S; and  
         enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
       
     
     
         32 . The compound according to  claim 31  wherein L is a direct bond.  
     
     
         33 . The compound according to  claim 31  wherein L is C 1-4 alkyldiyl.  
     
     
         34 . The compound according to  claim 31  wherein R 3  is phenyl.  
     
     
         35 . The compound according to  claim 31  wherein R 3  is pyridyl.  
     
     
         36 . The compound according to  claim 31  wherein R 3  is thienyl.  
     
     
         37 . The compound according to  claim 31  wherein R 4  is C 1-12 alkanyl.  
     
     
         38 . The compound according to  claim 31  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         39 . The compound according to  claim 38  wherein R 5  and R 6  are different.  
     
     
         40 . The compound according to  claim 31  wherein L is C 1-4 alkyldiyl, R 3  is phenyl, and one R 4  is C 1-12 alkanyl.  
     
     
         41 . The compound according to  claim 31  wherein R 3  is phenyl, and one R 4  is —N(R 5 )(R 6 ).  
     
     
         42 . The compound according to  claim 31  wherein R 3  is phenyl and two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkyl.  
     
     
         43 . The compound according to  claim 31  wherein Z is O.  
     
     
         44 . The compound according to  claim 31  wherein m is 0.  
     
     
         45 . The compound according to  claim 31  wherein R 2  is hydrogen.  
     
     
         46 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
         wherein:  
         R 1  is a substituent independently selected from the group consisting of hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
         m is 1 or 2;  
         R 2  is hydrogen or C 1-8 alkanyl;  
         L is a direct bond or C 1-4 alkyldiyl optionally substituted with a substituent selected from the group consisting of C 1-8 alkanyl, C 3-8 cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, halogen, C 1-8 alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C 1-3 )alkanylamino, and C 1-3 alkanylamino;  
         R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl;  
         R 4  is independently selected from the group consisting of C 1-8 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 16  fluorinated alkanyl, and —N(R 5 )(R 6 ); or both R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
         R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
         R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl;  
         wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
         n is 1, 2 or 3;  
         Z is O or S; and  
         enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
       
     
     
         47 . The compound according to  claim 46  wherein L is a direct bond.  
     
     
         48 . The compound according to  claim 46  wherein L is C 1-4 alkyldiyl.  
     
     
         49 . The compound according to  claim 46  wherein R 3  is phenyl.  
     
     
         50 . The compound according to  claim 46  wherein R 3  is pyridyl.  
     
     
         51 . The compound according to  claim 46  wherein R 3  is thienyl.  
     
     
         52 . The compound according to  claim 46  wherein R 4  is C 1-12 alkanyl.  
     
     
         53 . The compound according to  claim 46  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         54 . The compound according to  claim 46  wherein R 5  and R 6  are different.  
     
     
         55 . The compound according to  claim 46  wherein L is C 1-4 alkyldiyl, R 3  is phenyl, and one R 4  is C 1-12 alkanyl.  
     
     
         56 . The compound according to  claim 46  wherein R 3  is phenyl, and one R 4  is —N(R 5 )(R 6 ).  
     
     
         57 . The compound according to  claim 46  wherein R 3  is phenyl and two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkyl.  
     
     
         58 . The compound according to  claim 46  wherein Z is O.  
     
     
         59 . The compound according to  claim 46  wherein m is 0.  
     
     
         60 . The compound according to  claim 46  wherein R 2  is hydrogen.  
     
     
         61 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
         wherein:  
         R 1  is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
         m is 0, 1 or 2;  
         R 2  is hydrogen or C 1-8 alkanyl;  
         L is ethen-1,2-diyl;  
         R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl;  
         R 4  is independently selected from the group consisting of C 1-12 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 1-6  fluorinated alkanyl, halogen, and —N(R 5 )(R 6 ); or when n is 2 or 3, optionally two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
         R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
         R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl;  
         wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
         n is 1, 2 or 3;  
         Z is O or S; and  
         enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
       
     
     
         62 . The compound according to  claim 61  wherein R 3  is phenyl.  
     
     
         63 . The compound according to  claim 61  wherein R 3  is pyridyl.  
     
     
         64 . The compound according to  claim 61  wherein R 3  is thienyl.  
     
     
         65 . The compound according to  claim 61  wherein n is 1.  
     
     
         66 . The compound according to  claim 61  wherein n is 2 or 3 and R 4  is C 1-12 alkanyl.  
     
     
         67 . The compound according to  claim 61  wherein n is 2, one R 4  is halogen, and the other R 4  is C 1-6  fluorinated alkanyl.  
     
     
         68 . The compound according to  claim 61  wherein R 4  is C 1-6  fluorinated alkanyl.  
     
     
         69 . The compound according to  claim 61  R 4  is halogen.  
     
     
         70 . The compound according to  claim 61  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         71 . The compound according to  claim 67  wherein R 5  and R 6  are different.  
     
     
         72 . The compound according to  claim 61  wherein L is C 1-4 alkyldiyl, R 3  is phenyl, n is 1 and R 4  is C 1-12 alkanyl.  
     
     
         73 . The compound according to  claim 61  wherein R 3  is phenyl, n is 1 and R 4  is —N(R 5 )(R 6 ).  
     
     
         74 . The compound according to  claim 61  wherein R 3  is phenyl, n is 2 or 3, and two R 4 substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkyl.  
     
     
         75 . The compound according to  claim 61  wherein Z is O.  
     
     
         76 . The compound according to  claim 61  wherein m is 0.  
     
     
         77 . The compound according to  claim 61  wherein R 2  is hydrogen.  
     
     
         78 . A compound of Formula (I):  
       
         
           
           
               
               
           
         
         wherein:  
         R 1  is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent;  
         m is 0, 1 or 2;  
         R 2  is hydrogen or C 1-8 alkanyl;  
         L is a direct bond;  
         R 3  is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, and cyclohexyl;  
         R 4  is selected from the group consisting of C 1-12 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14  cyclic heteroalkanyl, C 1-6  fluorinated alkanyl, and —N(R 5 )(R 6 ), wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4  is optionally substituted with thienyl or phenyl; or when n is 2 or 3, optionally two R 4  substituents taken together form a C 3-14  cyclic heteroalkyl or C 3-14  cyclic alkanyl;  
         R 5  is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl;  
         R 6  is C 4-16  alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6  and one of R 4  taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5  and R 6  optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl; wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5  or R 6  are optionally and independently substituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl;  
         n is 1, 2 or 3;  
         Z is O or S; and  
         enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.  
       
     
     
         79 . The compound according to  claim 78  wherein L is a direct bond.  
     
     
         80 . The compound according to  claim 78  wherein R 3  is pyridyl.  
     
     
         81 . The compound according to  claim 78  wherein R 3  is thienyl.  
     
     
         82 . The compound according to  claim 78  wherein R 3  is furyl.  
     
     
         83 . The compound according to  claim 78  wherein R 3  is cyclohexyl.  
     
     
         84 . The compound according to  claim 78  wherein n is 1.  
     
     
         85 . The compound according to  claim 78  wherein n is 2 or 3 and R 4  is C 1-12 alkanyl.  
     
     
         86 . The compound according to  claim 78  wherein R 4  is —N(R 5 )(R 6 ).  
     
     
         87 . The compound according to  claim 86  wherein R 5  and R 6  are different.  
     
     
         88 . The compound according to  claim 78  wherein Z is O.  
     
     
         89 . The compound according to  claim 78  wherein m is 0.  
     
     
         90 . The compound according to  claim 78  wherein R 2  is hydrogen.  
     
     
         91 . A compound selected from the group consisting of 
 1-Acetyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Benzoyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Butyryl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexanecarbonyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-carboxylic acid quinolin-3-ylamide;    1-Methyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid quinolin-3-ylamide;    1-Methyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid quinolin-3-ylamide;    1-Pentyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    2-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-acetamide;    2-(4-Pentyl-phenyl)-N-quinolin-3-yl-acetamide;    2-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acetamide;    2-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    2-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;    2,3-Dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    2-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acetamide;    2-Chloro-4-(cyclohexylmethyl-amino)-N-quinolin-3-yl-benzamide;    2-Chloro-4-pentylamino-N-quinolin-3-yl-benzamide;    2-Heptylamino-N-quinolin-3-yl-benzamide;    2-Pentylamino-N-quinolin-3-yl-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;    3-(1-Cyclohexylmethyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;    3-(1-Propyl-1H-indol-5-yl)-N-quinolin-3-yl-propionamide,    3-(1-Propyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;    3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-acrylamide;    3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-propionamide;    3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-Cyclohexylmethyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-Pentyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-Pentyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;    3-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    3-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;    3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    3-[4-(Methyl-phenethyl-amino)-phenyl]-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;    3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(Benzyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(Cyclohexyl-methyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;    3-{4-(Cyclohexyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(Cyclohexyl methyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;    3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(Methyl-propyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;    3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;    3-Cyclohexylamino-N-quinolin-3-yl-benzamide;    3-Dipentylamino-N-quinolin-3-yl-benzamide;    3-Heptylamino-N-quinolin-3-yl-benzamide;    3-Indan-5-yl-N-quinolin-3-yl-propionamide;    3-Methyl-4-(methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;    3-Methyl-4-pentylamino-N-quinolin-3-yl-benzamide;    3-Pentylamino-N-quinolin-3-yl-benzamide;    4-(1,3-Dihydro-isoindol-2-yl)-N-quinolin-3-yl-benzamide;    4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-N-quinolin-3-yl-benzamide;    4-(2,6-Dimethyl-morpholin-4-yl)-N-quinolin-3-yl-benzamide;    4-(3,5-Dimethyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;    4-(3-Methyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(4-Benzoyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(4-Phenylacetyl-piperazin-1-yl)-N-quinolin-3-yl-benzamide;    4-(4-Phenyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(4-Propyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(Acetyl-cyclohexyl-amino)-N-quinolin-3-yl-benzamide;    4-(Benzyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Benzyl-pentyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexanecarbonyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-N-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl methyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl methyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexylmethyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-propyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-butyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-hexyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-propyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-tetradecyl-amino)-N-quinolin-3-yl-benzamide;    4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Phenethyl-propyl-amino)-N-quinolin-3-yl-benzamide;    4-[1,4′]Bipiperidinyl-1′-yl-N-quinolin-3-yl-benzamide;    4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    4-{4-(1,1-Dimethyl-pentyl)-phenyl}-but-3-enoic acid quinolin-3-ylamide;    4-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl-butyramide;    4-{4-(1,1-Dimethyl-propyl)-phenyl}-but-3-enoic acid quinolin-3-ylamide;    4-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-butyramide;    4-{Methyl-(3-methyl-butyl)-amino}-N-quinolin-3-yl-benzamide;    4-{Methyl-(3-phenyl-allyl)-amino}-N-quinolin-3-yl-benzamide;    4-{Methyl-(3-phenyl-propyl)-amino}-N-quinolin-3-yl-benzamide;    4-{Methyl-(tetrahydro-pyran4-yl)-amino}-N-quinolin-3-yl-benzamide;    4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azocan-1-yl-N-quinolin-3-yl-benzamide;    4-Azonan-1-yl-N-quinolin-3-yl-benzamide;    4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    4-Butoxy-N-quinolin-3-yl-benzamide;    4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;    4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;    4-Cycloheptylamino-N-quinolin-3-yl-benzamide;    4-Cyclohexylamino-N-methyl-N-quinolin-3-yl-benzamide;    4-Cyclohexylamino-N-quinolin-3-yl-benzamide;    4-Cyclopentylamino-N-quinolin-3-yl-benzamide;    4-Dibenzylamino-N-quinolin-3-yl-benzamide;    4-Dibutylamino-N-quinolin-3-yl-benzamide;    4-Dihexylamino-N-quinolin-3-yl-benzamide;    4-Dipentylamino-N-quinolin-3-yl-benzamide;    4-Dipropylamino-N-quinolin-3-yl-benzamide;    4-Morpholin-4-yl-N-quinolin-3-yl-benzamide;    4-Pentylamino-N-quinolin-3-yl-benzamide;    4-Phenethylamino-N-quinolin-3-yl-benzamide;    4-Piperazin-1-yl-N-quinolin-3-yl-benzamide;    4-Piperidin-1-yl-N-quinolin-3-yl-benzamide;    4-Propyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    4-Pyrrolidin-1-yl-N-quinolin-3-yl-benzamide;    4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;    4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;    5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid quinolin-3-ylamide;    5,6,7,8-Tetrahydro-naphthalene-2-carboxylic acid quinolin-3-ylamide;    5-Chloro-1H-indole-2-carboxylic acid quinolin-3-ylamide;    5-Pentyl-thiophene-2-carboxylic acid quinolin-3-ylamide;    6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;    6-(Benzyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;    6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;    6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;    6-(Heptyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;    6-(Methyl-pentyl-amino)-N-quinolin-3-yl-nicotinamide;    6-(Methyl-phenethyl-amino)-N-quinolin-3-yl-nicotinamide;    6-Azepan-1-yl-N-quinolin-3-yl-nicotinamide;    6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;    6-Cyclohexylamino-N-quinolin-3-yl-nicotinamide;    6-Pentylamino-N-quinolin-3-yl-nicotinamide;    cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;    cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;    N-Quinolin-3-yl-3-(3-trifluoromethyl-phenyl)-acrylamide;    N-Quinolin-3-yl-3-(4-tricyclo{5.3.1.13,9}dodec-1-yl-phenyl)-propionamide;    N-Quinolin-3-yl-3-(4-trifluoromethyl-phenyl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;    N-Quinolin-3-yl-3-(5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;    N-Quinolin-3-yl-4-(tetrahydro-pyran4-ylamino)-benzamide;    N-Quinolin-3-yl-4-thiomorpholin-4-yl-benzamide;    R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;    trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;    4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;    3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;    3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;    1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;    3-Phenyl-propynoic acid quinolin-3-ylamide;    trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and    2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.    
     
     
         92 . A compound selected from the group consisting of 
 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid quinolin-3-ylamide;    1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;    3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;    4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;    4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azocan-1-yl-N-quinolin-3-yl-benzamide;    4-Azonan-1-yl-N-quinolin-3-yl-benzamide;    4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid quinolin-3-ylamide;    6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;    6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;    cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;    cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;    R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;    trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;    4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;    3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;    3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;    1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;    3-Phenyl-propynoic acid quinolin-3-ylamide;    trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and    2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.    
     
     
         93 . A compound selected from the group consisting of 
 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;    4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;    4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;    4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Dec4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;    4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azocan-1-yl-N-quinolin-3-yl-benzamide;    4-Azonan-1-yl-N-quinolin-3-yl-benzamide;    4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide;    6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;    R 4 -{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;    3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;    3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;    1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;    3-Phenyl-propynoic acid quinolin-3-ylamide;    trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and    2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.    
     
     
         94 . A compound selected from the group consisting of 
 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;    3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;    4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;    4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;    4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;    4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    4-Azocan-1-yl-N-quinolin-3-yl-benzamide;    4-Azonan-1-yl-N-quinolin-3-yl-benzamide;    6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;    R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;    5 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;    3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;    3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;    1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;    3-Phenyl-propynoic acid quinolin-3-ylamide;    trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and    2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.    
     
     
         95 . A compound selected from the group consisting of 
 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;    3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;    3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;    4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;    4-Azepan-1-yl-N-quinolin-3-yl-benzamide;    6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;    4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;    3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;    N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;    N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;    4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;    4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;    3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;    3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;    N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;    1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;    1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;    N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;    4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;    4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;    4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;    3-Phenyl-propynoic acid quinolin-3-ylamide;    trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;    3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and    2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.    
     
     
         96 . A pharmaceutical composition comprising a compound, salt or solvate according to  claim 1  admixed with a pharmaceutically acceptable carrier, excipient or diluent.  
     
     
         97 . A veterinary composition comprising a compound, salt or solvate according to  claim 1  admixed with a veterinarily acceptable carrier, excipient or dilluent.  
     
     
         98 . A method of treating or preventing a disease or condition in a mammal which disease or condition is affected by the modulation of one or more vanilloid receptors, which method comprises administering to a mammal in need of such treatment or prevention a therapeutically effective amount of a compound, salt or solvate of  claim 1 .  
     
     
         99 . A method for preventing or treating a chronic-pain causing disease or condition, an acute-pain causing disease or condition, or a pulmonary dysfunction comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 1 .  
     
     
         100 . A method for preventing or treating a disease or condition, wherein said disease or condition causes inflammatory pain, burning pain, itch urinary incontinence, or chronic obstructive pulmonary disease, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 1 .  
     
     
         101 . A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 1 .  
     
     
         102 . The method of  claim 101  wherein the disease or condition is ulcerative colitis.  
     
     
         103 . The method of  claim 101  wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.  
     
     
         104 . The method of  claim 101  wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.  
     
     
         105 . The method of  claim 101  wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.  
     
     
         106 . A kit comprising in one or more containers an amount of the composition of  claim 1  effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.  
     
     
         107 . A pharmaceutical composition comprising a compound, salt or solvate according to  claim 17  admixed with a pharmaceutically acceptable carrier, excipient or diluent.  
     
     
         108 . A veterinary composition comprising a compound, salt or solvate according to  claim 17  admixed with a veterinarily acceptable carrier, excipient or dilluent.  
     
     
         109 . A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 17 .  
     
     
         110 . The method of  claim 109  wherein the disease or condition is ulcerative colitis.  
     
     
         111 . The method of  claim 109  wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.  
     
     
         112 . The method of  claim 109  wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.  
     
     
         113 . The method of  claim 109  wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.  
     
     
         114 . A kit comprising in one or more containers an amount of the composition of  claim 17  effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.  
     
     
         115 . A pharmaceutical composition comprising a compound, salt or solvate according to  claim 31  admixed with a pharmaceutically acceptable carrier, excipient or diluent.  
     
     
         116 . A veterinary composition comprising a compound, salt or solvate according to  claim 31  admixed with a veterinarily acceptable carrier, excipient or dilluent.  
     
     
         117 . A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 31 .  
     
     
         118 . The method of  claim 117  wherein the disease or condition is ulcerative colitis.  
     
     
         119 . The method of  claim 117  wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.  
     
     
         120 . The method of  claim 117  wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.  
     
     
         121 . The method of  claim 117  wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.  
     
     
         122 . A kit comprising in one or more containers an amount of the composition of  claim 31  effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.  
     
     
         123 . A pharmaceutical composition comprising a compound, salt or solvate according to  claim 61  admixed with a pharmaceutically acceptable carrier, excipient or diluent.  
     
     
         124 . A veterinary composition comprising a compound, salt or solvate according to  claim 61  admixed with a veterinarily acceptable carrier, excipient or dilluent.  
     
     
         125 . A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 61 .  
     
     
         126 . The method of  claim 125  wherein the disease or condition is ulcerative colitis.  
     
     
         127 . The method of  claim 125  wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.  
     
     
         128 . The method of  claim 125  wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.  
     
     
         129 . The method of  claim 125  wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.  
     
     
         130 . A kit comprising in one or more containers an amount of the composition of  claim 61  effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.  
     
     
         131 . A pharmaceutical composition comprising a compound, salt or solvate according to  claim 78  admixed with a pharmaceutically acceptable carrier, excipient or diluent.  
     
     
         132 . A veterinary composition comprising a compound, salt or solvate according to  claim 78  admixed with a veterinarily acceptable carrier, excipient or dilluent.  
     
     
         133 . A method for preventing or treating a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma, said method comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of a compound, salt or solvate of  claim 78 .  
     
     
         134 . The method of  claim 133  wherein the disease or condition is ulcerative colitis.  
     
     
         135 . The method of  claim 133  wherein said therapeutically effective amount comprises a dose range of from about 0.001 mg to about 1,000 mg.  
     
     
         136 . The method of  claim 133  wherein said therapeutically effective amount comprises a dose range of from about 0.1 mg to about 500 mg.  
     
     
         137 . The method of  claim 133  wherein said therapeutically effective amount comprises a dose range of from about 1 mg to about 250 mg.  
     
     
         138 . A kit comprising in one or more containers an amount of the composition of  claim 133  effective to treat or prevent a disease or condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn, sunburn, snake bite (in particular, venomous snake bite), spider bite, insect sting, neurogenic bladder, benign prostatic hypertrophy, interstitial cystitis, urinary tract infection, cough asthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis, cholecystitis, pancreatitis, postmastectomy pain syndrome, oral neuropathic pain, Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache, tension headache, labor, childbirth, intestinal gas, menstrual cramps, cancer, and trauma.